Yayın:
Sequential vs Myeloablative vs Reduced Intensity Conditioning for Patients with Myelodysplastic Syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A Retrospective Study by the Chronic Malignancies Working Party of the EBMT

dc.contributor.authorPotter, V.
dc.contributor.authorGras, L.
dc.contributor.authorKoster, L.
dc.contributor.authorKroger, N.
dc.contributor.authorSockel, K.
dc.contributor.authorGanser, A.
dc.contributor.authorFinke, J.
dc.contributor.authorLabussiere-Wallet, H.
dc.contributor.authorPeffault de Latour, R.
dc.contributor.authorKoc, Y.
dc.contributor.authorSalmenniemi, U.
dc.contributor.authorSmidstrup Friis, L.
dc.contributor.authorJindra, P.
dc.contributor.authorSchroeder, T.
dc.contributor.authorTischer, J.
dc.contributor.authorArat, M.
dc.contributor.authorPascual Cascon, M.
dc.contributor.authorde Wreede, L. C.
dc.contributor.authorHayden, P.
dc.contributor.authorRaj, K.
dc.contributor.authorDrozd-Sokolowska, J.
dc.contributor.authorScheid, C.
dc.contributor.authorMcLornan, D. P.
dc.contributor.authorRobin, M.
dc.contributor.authorYakoub-Agha, I.
dc.date.accessioned2026-01-24T22:55:06Z
dc.date.issued2023-03-07
dc.description.abstract<title>Abstract</title> <p>The optimal conditioning for patients with higher risk MDS receiving potentially curative allogeneic haematopoietic stem cell transplant(allo-HCT) remains to be defined. This is particularly the case for patients with excess of blasts at time of allo-HCT. Sequential(Seq) conditioning, whereby chemotherapy is followed rapidly by transplant conditioning, offers an opportunity to decrease disease burden, potentially improving outcomes allo-HCT outcomes. Herein we present the only analysis comparing Seq to myeloablative(MAC) and reduced intensity conditioning(RIC) specifically focussed on MDS patients with excess of blasts at allo-HCT. 303 patients were identified in the EBMT registry, receiving RIC(n=158,) Seq(n=105,), and MAC(n=40, ). Median follow-up was 67.2 months and median age at allo-HCT was 59.5 years(IQR 53.5 - 65.6). For the entire cohort, 3yr overall survival(OS) was 50%(95% CI45-56%) and relapse free survival(RFS) 45%(95%CI 40-51%). No differences in outcomes were observed per protocol with respect to OS and RFS. On multivariable analysis, lower performance status, worse IPSS-R cytogenetics, sibling donor (compared to 8/8 MUD) and &gt;20% blasts at allo-HCT were associated with worse outcomes. In conclusion, the Seq protocol did little to influence the outcome in this high-risk group of patients, with outcomes mostly determined by baseline disease risk and patient characteristics such as performance status.</p>
dc.description.urihttps://doi.org/10.21203/rs.3.rs-2604480/v1
dc.description.urihttps://doi.org/10.1038/s41409-023-02111-3
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/37993503
dc.description.urihttps://hal.univ-lille.fr/hal-04512607v1
dc.description.urihttps://hdl.handle.net/1887/3748475
dc.description.urihttps://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85177460879
dc.description.urihttps://www.researchsquare.com/article/rs-2604480/v1
dc.description.urihttps://www.ncbi.nlm.nih.gov/pubmed/37993503
dc.description.urihttps://doi.org/https://doi.org/10.1038/s41409-023-02111-3
dc.identifier.doi10.21203/rs.3.rs-2604480/v1
dc.identifier.eissn1476-5365
dc.identifier.endpage231
dc.identifier.issn0268-3369
dc.identifier.openairedoi_dedup___::31e410304f47490b571d326c77530e8d
dc.identifier.orcid0000-0001-5103-9966
dc.identifier.orcid0000-0002-1799-5927
dc.identifier.orcid0000-0002-8415-7069
dc.identifier.orcid0000-0002-1653-7959
dc.identifier.orcid0000-0003-1821-1976
dc.identifier.orcid0000-0003-2039-8557
dc.identifier.orcid0000-0002-7667-9369
dc.identifier.orcid0000-0003-1374-4503
dc.identifier.orcid0000-0002-8258-354x
dc.identifier.orcid0000-0002-4562-6264
dc.identifier.orcid0000-0003-1224-091x
dc.identifier.orcid0000-0003-1388-9876
dc.identifier.orcid0000-0003-4524-8782
dc.identifier.startpage224
dc.identifier.urihttps://hdl.handle.net/11527/39160
dc.identifier.volume59
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofBone Marrow Transplantation
dc.rightsOPEN
dc.sdg.typeGoal 3: Good Health and Well-being
dc.subjectTransplantation Conditioning
dc.subjectMedizin
dc.subjectHematopoietic Stem Cell Transplantation
dc.subjectGraft vs Host Disease
dc.subjectMiddle Aged
dc.subject[SDV] Life Sciences [q-bio]
dc.subjectMyelodysplastic Syndromes
dc.subjectChronic Disease
dc.subjectHumans
dc.subjectTransplantation, Homologous
dc.subjectNeoplasm Recurrence, Local
dc.subjectAged
dc.subjectRetrospective Studies
dc.titleSequential vs Myeloablative vs Reduced Intensity Conditioning for Patients with Myelodysplastic Syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A Retrospective Study by the Chronic Malignancies Working Party of the EBMT
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyonlar